Business Context and Reporting Period
Company: Corniche Group Incorporated (Note: Metadata listed "Lisata Therapeutics" is incorrect; the filing is for Corniche Group).
Reporting Period: Quarterly period ended June 30, 1998.
Operational Status: The Company has been inactive since February 1996 following the receivership of its UK subsidiaries. In March 1998, a change in control occurred via the issuance of Series B Preferred Stock. New management is exploring opportunities in the property and casualty specialty insurance sector but has not yet generated operating revenue.
Key Financial Metrics
| Metric | Q2 1998 | Q2 1997 |
|---|---|---|
| Net Sales | $0 | $0 |
| Operating Loss | $(134,237) | $(120,816) |
| Net Loss | $(137,214) | $(138,686) |
| Cash and Equivalents (End of Period) | $1,126,383 | $263,428 |
| Net Cash Used in Operations | $(79,181) | $(222,739) |
| Net Cash Provided by Financing | $76,500 | $473,000 |
| Total Assets | $1,140,017 | N/A |
| Total Liabilities | $330,806 | N/A |
Debt and Liquidity: The Company has no long-term debt listed on the balance sheet. Current liabilities include $224,107 in preferred stock dividends payable. Liquidity is supported by cash reserves of approximately $1.13 million, derived largely from prior securities offerings.
Material Changes vs. Prior Period
- Change in Control: On March 4, 1998, the Company issued 765,000 shares of Series B Convertible Redeemable Preferred Stock to new investors, resulting in a change of control and dilution of existing common stockholders by approximately 57%.
- Capital Structure: The par value of Common Stock was reduced from $0.10 to $0.001 per share. Series B Preferred Stock was created with a par value of $0.01.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased by $13,421 compared to the prior year quarter, primarily due to legal fees ($60,000) associated with the change in control and corporate restructuring.
- Financing Activity: The Company raised $76,500 in the current quarter through the issuance of Series B Preferred Stock, compared to $873,000 in common stock proceeds in the prior year quarter.
Outlook, Risks, and Management Commentary
- Business Plan: Management is endeavoring to establish operations in the property and casualty specialty insurance markets. No assurance is given that the Company will obtain necessary licenses or consummate planned acquisitions.
- Capital Needs: The Company explicitly states it requires additional capital to meet licensing surplus requirements and fund acquisitions. It intends to undertake a private placement of equity securities.
- Redemption Risk: The Series B Preferred Stock is redeemable by the Company for $0.10 per share ($76,500 total) between March 31, 2000, and June 30, 2000, unless specific "Trigger Conditions" are met (e.g., stock price maintenance, raising $2.5M equity, or generating $1M quarterly revenue).
- Auditor Change: The Company terminated its relationship with Simontacchi & Co. LLP and engaged Weinick, Sanders & Co. as of August 12, 1998. No disagreements were reported regarding accounting principles.
Investor Verification Checklist
- Verify the status of the planned transition into the insurance sector and any progress on obtaining state licenses.
- Confirm the timeline and terms of the intended private placement to raise the necessary capital for operations.
- Review the specific "Trigger Conditions" for the Series B Preferred Stock redemption to understand potential dilution or cash outflow risks in 2000.
- Assess the sustainability of the current cash burn rate ($79k per quarter) against the $1.13 million cash balance.
- Validate the new management team's track record in the specialty insurance market.